236 related articles for article (PubMed ID: 9469328)
1. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
Dombernowsky P; Smith I; Falkson G; Leonard R; Panasci L; Bellmunt J; Bezwoda W; Gardin G; Gudgeon A; Morgan M; Fornasiero A; Hoffmann W; Michel J; Hatschek T; Tjabbes T; Chaudri HA; Hornberger U; Trunet PF
J Clin Oncol; 1998 Feb; 16(2):453-61. PubMed ID: 9469328
[TBL] [Abstract][Full Text] [Related]
2. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
[TBL] [Abstract][Full Text] [Related]
3. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group.
Goss PE; Winer EP; Tannock IF; Schwartz LH
J Clin Oncol; 1999 Jan; 17(1):52-63. PubMed ID: 10458218
[TBL] [Abstract][Full Text] [Related]
5. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
Tominaga T; Adachi I; Sasaki Y; Tabei T; Ikeda T; Takatsuka Y; Toi M; Suwa T; Ohashi Y
Ann Oncol; 2003 Jan; 14(1):62-70. PubMed ID: 12488294
[TBL] [Abstract][Full Text] [Related]
6. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group.
Buzdar A; Jonat W; Howell A; Jones SE; Blomqvist C; Vogel CL; Eiermann W; Wolter JM; Azab M; Webster A; Plourde PV
J Clin Oncol; 1996 Jul; 14(7):2000-11. PubMed ID: 8683230
[TBL] [Abstract][Full Text] [Related]
7. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
8. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
Gershanovich M; Chaudri HA; Campos D; Lurie H; Bonaventura A; Jeffrey M; Buzzi F; Bodrogi I; Ludwig H; Reichardt P; O'Higgins N; Romieu G; Friederich P; Lassus M
Ann Oncol; 1998 Jun; 9(6):639-45. PubMed ID: 9681078
[TBL] [Abstract][Full Text] [Related]
9. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.
Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
J Clin Oncol; 2000 Apr; 18(7):1399-411. PubMed ID: 10735887
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.
Dranitsaris G; Leung P; Mather J; Oza A
Anticancer Drugs; 2000 Aug; 11(7):591-601. PubMed ID: 11036964
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
12. Pivotal trials of letrozole: a new aromatase inhibitor.
Smith IE
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):41-4. PubMed ID: 9556791
[TBL] [Abstract][Full Text] [Related]
13. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.
Jonat W; Howell A; Blomqvist C; Eiermann W; Winblad G; Tyrrell C; Mauriac L; Roche H; Lundgren S; Hellmund R; Azab M
Eur J Cancer; 1996 Mar; 32A(3):404-12. PubMed ID: 8814682
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of letrozole for advanced breast cancer in postmenopausal patients.
Ansari TN; Mahmood A; Hussain I; Samad A
J Coll Physicians Surg Pak; 2005 Apr; 15(4):204-6. PubMed ID: 15857590
[TBL] [Abstract][Full Text] [Related]
15. [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group].
Abe R; Tominaga T; Nomizu T; Nomura Y; Takashima S; Koyama H; Sano M; Tohge T; Ueo H; Ikeda S; Ohashi Y;
Gan To Kagaku Ryoho; 2002 May; 29(5):729-40. PubMed ID: 12040677
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
[TBL] [Abstract][Full Text] [Related]
17. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
Lamb HM; Adkins JC
Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
[TBL] [Abstract][Full Text] [Related]
18. Clinical overview of anastrozole--a new selective oral aromatase inhibitor.
Jonat W
Oncology; 1997; 54 Suppl 2():15-8. PubMed ID: 9394855
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Mouridsen H; Chaudri-Ross HA
Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]